Exchange: NASDAQ·Updated 04:03 AM EDT
News
all
press releases
Cathie Wood Bought The NVDA Dip Across Five Funds – Here’s What Else ARK Bought And Sold
ARKK and ARKG completely exited their respective positions in 10x Genomics.
Stocktwits
More News
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.
Zacks
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +39.13% and +2.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
10x Genomics Reports Second Quarter 2026 Financial Results
10x Genomics Reports Second Quarter 2026 Financial Results 10x Genomics Reports Second Quarter 2026 Financial Results PR Newswire PLEASANTON, Calif., Aug. 6, 2026 PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc.(Nasdaq: TXG), the life science technology leader focused on...
PR Newswire
10x Genomics (TXG) Upgraded to Buy: Here's Why
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care 10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial...
PR Newswire
Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell?
TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deals, but near-term margin pressure remains.
Zacks
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026 10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026 PR Newswire PLEASANTON, Calif., July 15, 2026 PLEASANTON, Calif., July 15, 2026 /PRNewswire/ --10x Genomics, Inc.(Nasdaq: TXG), the life...
PR Newswire

Advertisement|Remove ads.